Per Lundin
Directeur/Membre du Conseil chez COMBIGENE AB
Profil
Dr. Per Lundin is a Chief Executive Officer & Director at Evox Therapeutics Ltd.
He is on the Board of Directors at Evox Therapeutics Ltd., JDRF International and CombiGene AB.
Dr. Lundin was previously employed as a Non-Executive Director by IsletOne Therapeutics and a Manager-European Law Firm Market by Thomson Reuters Holdings AB.
He received his graduate degree from Royal Institute of Technology, an MBA from Stockholm Business School and a doctorate degree from Karolinska Institutet.
Postes actifs de Per Lundin
Sociétés | Poste | Début |
---|---|---|
COMBIGENE AB | Directeur/Membre du Conseil | 01/01/2020 |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Fondateur | 01/01/2016 |
JDRF International
JDRF International Miscellaneous Commercial ServicesCommercial Services JDRF International is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. JDRF find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. It was founded in 1970 and is headquartered in New York, NY. | Directeur/Membre du Conseil | - |
Anciens postes connus de Per Lundin
Sociétés | Poste | Fin |
---|---|---|
IsletOne Therapeutics | Fondateur | 01/04/2016 |
Thomson Reuters Holdings AB | Corporate Officer/Principal | 01/04/2016 |
Formation de Per Lundin
Karolinska Institutet | Doctorate Degree |
Royal Institute of Technology | Graduate Degree |
Stockholm Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
COMBIGENE AB | Health Technology |
Entreprise privées | 4 |
---|---|
JDRF International
JDRF International Miscellaneous Commercial ServicesCommercial Services JDRF International is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. JDRF find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. It was founded in 1970 and is headquartered in New York, NY. | Commercial Services |
Thomson Reuters Holdings AB | |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Health Technology |
IsletOne Therapeutics |